Comparison · NCT02132767-3d255dbe
Rate Control vs Rhythm Control: Heart Rhythm Comparison
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rate Control vs Rhythm Control: Heart Rhythm Comparison. Trial comparisons, record NCT02132767-3d255dbe. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02132767-3d255dbe
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.909 | 0.866 | 0.939 | wilson | |
| Risk in group 2 | 0.899 | 0.855 | 0.931 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0099 | -0.0434 | 0.063 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.954 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 1.12 | 0.614 | 2.05 | log | |
| Number needed to treat, for one more participant with the outcome on Rate Control than on Rhythm Control | 101 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rate Control | Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is \< 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (\<60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.~Rate Control Agents:~Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin | 220 | 242 | OG000 |
| Group 2 | Rhythm Control | Patients assigned to an initial strategy of rhythm control will be treated with amiodarone alone or amiodarone plus direct current (DC) cardioversion if amiodarone alone does not eliminate AF within 48 hours. For patients who are hemodynamically stable but remain in AF, at least 24 hours of amiodarone should be administered before cardioversion is attempted. Cardioversion should be attempted, if possible, prior to the 48 hour duration to avoid the need for a TEE guided approach.~If AF has been present for ≥ 48 hours and the patient has not been therapeutically anticoagulated, cardioversion should be TEE guided. When deemed to be clinically appropriate, patients in the rhythm control arm may also be treated with a rate control medication (e.g. beta blocker). In particular, a rate control medication may be indicated at the onset of AF. | 223 | 248 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Heart Rhythm Comparison
- Description
- Compare heart rhythm (patients in sustained, stable non-AF rhythm) between treatment arms at 30 days after randomization
- Time frame
- 30 days after randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
- NCT number
- NCT02132767
- Phases
- PHASE3
- Conditions
- Postoperative Atrial Fibrillation
- Interventions
- Amiodarone, DC-cardioversion, Rate Control
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Results first posted
- 2017-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02132767?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02132767-3d255dbe